The stock of Assembly Biosciences Inc (NASDAQ:ASMB) hit a new 52-week high and has $22.38 target or 67.00% above today’s $13.40 share price. The 9 months bullish chart indicates low risk for the $226.81 million company. The 1-year high was reported on Nov, 2 by Barchart.com. If the $22.38 price target is reached, the company will be worth $151.96M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 18,265 shares traded hands. Assembly Biosciences Inc (NASDAQ:ASMB) has risen 176.49% since March 31, 2016 and is uptrending. It has outperformed by 173.97% the S&P500.
Analysts await Assembly Biosciences Inc (NASDAQ:ASMB) to report earnings on November, 14.
According to Zacks Investment Research, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.”
More important recent Assembly Biosciences Inc (NASDAQ:ASMB) news were published by: Globenewswire.com which released: “Assembly Biosciences Announces Participation in HBV Scientific Meetings in …” on September 21, 2016, also Globenewswire.com published article titled: “Assembly Biosciences Announces Key Additions to Microbiome Team”, Globenewswire.com published: “Assembly Biosciences Expands Senior Leadership Team” on January 11, 2016. More interesting news about Assembly Biosciences Inc (NASDAQ:ASMB) was released by: Money.Cnn.com and their article: “Assembly Biosciences Presents Clinical Data at Drug Formulation …” with publication date: January 27, 2016.
ASMB Company Profile
Assembly Biosciences, Inc., incorporated on October 7, 2005, is a biotechnology company. The Firm is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. The Firm has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C (HBc) functions. The Company’s Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections (CDI). Using its microbiome platform, the Company is developing additional product candidates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.